Beeline’s oral lupus drug afimetoran delivers positive Phase 2 results on September 10, 2026 Afimetoran Beeline Medicines Clinical Trials development aspects Encephalitis, St. Louis Lupus Erythematosus, Systemic Phase 2 SRI-4 TLR7/8 inhibitor +
Alumis plans biomarker-focused Phase III lupus trial after LUMUS miss on September 01, 2026 Alumis EMA envudeucitinib IFNGS-high LUMUS Lupus Erythematosus, Systemic Multiple Acyl Coenzyme A Dehydrogenase Deficiency Phase IIb Phase III TYK2 inhibitor United States Food and Drug Administration +
Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease on July 09, 2026 Allogeneic Allogeneic Anti-CD19 1XX-CAR T-cells FT819 Autoimmune Diseases Automobiles B-Lymphocytes Depletion Encephalitis, St. Louis FT839 Identifier Lupus Erythematosus, Systemic Lupus Nephritis Phase 1/II RMAT +
Spotlight On: Cabaletta Bio's Small but Mighty Breakthrough for CAR-T in Autoimmune Arena on October 15, 2025 Autoimmune Diseases B-Lymphocytes Cabaletta Bio CAR-T therapy Depletion Lupus Erythematosus, Systemic Myositis Pemphigus Vulgaris rese-cel Systemic Scleroderma +
AstraZeneca's Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment on September 18, 2025 anifrolumab AstraZeneca Clinical Trials disease activity Encephalitis, St. Louis Lupus Erythematosus, Systemic Phase III Saphnelo Self-Injectable subcutaneous TULIP-SC trial +
Zenas BioPharma Secures $300M Royalty Deal for Obexelimab FDA Approvals on September 02, 2025 Approved Autoimmune Diseases IgG4-Related Disease Lupus Erythematosus, Systemic Obexelimab Phase 3 INDIGO trial royalty Royalty Pharma United States Food and Drug Administration Zenas BioPharma +